A Post Marketing, Multi-Center, Trial to Measure Human Anti-Human Antibodies (HAHA) to Soliris (Eculizumab) in Patients With Paroxysmal Nocturnal Hemoglobinuria
To determine the long term effect of Soliris (eculizumab) treatment on the presence of human
anti-human antibodies (HAHA) in Paroxysmal Nocturnal Hemoglobinuria (PNH) patients.
Time Perspective: Prospective
To summarize the proportion of patients with neutralizing HAHA antibodies.
Six (6) months
United States: Institutional Review Board
|Cleveland Clinic Florida||Weston, Florida 33331|
|Maine Cancer Center of Medicine||Scarborough, Maine|
|University Park Hematology Oncology||Englewood, Colorado 80113|